News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
434,378 Results
Type
Article (24121)
Company Profile (133)
Press Release (410124)
Multimedia
Podcasts (92)
Webinars (14)
Section
Business (131587)
Career Advice (929)
Deals (23024)
Drug Delivery (99)
Drug Development (60984)
Employer Resources (81)
FDA (9629)
Job Trends (9490)
News (228217)
Policy (20390)
Tag
Academia (1147)
Accelerated approval (9)
Adcomms (22)
Allergies (71)
Alliances (31074)
ALS (88)
Alzheimer's disease (1048)
Antibody-drug conjugate (ADC) (151)
Approvals (9693)
Artificial intelligence (264)
Autoimmune disease (30)
Automation (13)
Bankruptcy (211)
Best Places to Work (7258)
BIOSECURE Act (13)
Biosimilars (121)
Biotechnology (59)
Bladder cancer (83)
Brain cancer (30)
Breast cancer (296)
Cancer (2405)
Cardiovascular disease (185)
Career advice (756)
Career pathing (21)
CAR-T (107)
CDC (8)
Cell therapy (315)
Cervical cancer (21)
Clinical research (52013)
Collaboration (845)
Compensation (409)
Complete response letters (27)
COVID-19 (1348)
CRISPR (44)
C-suite (282)
Cystic fibrosis (89)
Data (2565)
Decentralized trials (2)
Denatured (22)
Depression (53)
Diabetes (253)
Diagnostics (3040)
Digital health (15)
Diversity (8)
Diversity, equity & inclusion (23)
Drug discovery (116)
Drug pricing (139)
Drug shortages (33)
Duchenne muscular dystrophy (118)
Earnings (58682)
Editorial (40)
Employer branding (10)
Employer resources (77)
Events (76681)
Executive appointments (704)
FDA (10909)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (3)
Frontotemporal dementia (5)
Funding (664)
Gene editing (91)
Generative AI (21)
Gene therapy (273)
GLP-1 (722)
Government (2494)
Grass and pollen (6)
Guidances (161)
Healthcare (9380)
HIV (34)
Huntington's disease (23)
IgA nephropathy (37)
Immunology and inflammation (135)
Immuno-oncology (10)
Indications (35)
Infectious disease (1478)
Inflammatory bowel disease (118)
Inflation Reduction Act (11)
Influenza (39)
Intellectual property (93)
Interviews (126)
IPO (10444)
IRA (50)
Job creations (2590)
Job search strategy (679)
Kidney cancer (11)
Labor market (38)
Layoffs (324)
Leadership (18)
Legal (4722)
Liver cancer (60)
Longevity (8)
Lung cancer (370)
Lymphoma (177)
Machine learning (9)
Management (31)
Manufacturing (347)
MASH (78)
Medical device (4954)
Medtech (4957)
Mergers & acquisitions (13120)
Metabolic disorders (720)
Multiple sclerosis (80)
NASH (22)
Neurodegenerative disease (105)
Neuropsychiatric disorders (33)
Neuroscience (1616)
NextGen: Class of 2025 (3211)
Non-profit (1651)
Now hiring (34)
Obesity (397)
Opinion (213)
Ovarian cancer (71)
Pain (104)
Pancreatic cancer (95)
Parkinson's disease (150)
Partnered (12)
Patents (233)
Patient recruitment (124)
Peanut (31)
People (37990)
Pharmaceutical (75)
Pharmacy benefit managers (25)
Phase I (15729)
Phase II (22343)
Phase III (17927)
Pipeline (1393)
Policy (177)
Postmarket research (1939)
Preclinical (6052)
Press Release (33)
Prostate cancer (131)
Psychedelics (23)
Radiopharmaceuticals (203)
Rare diseases (382)
Real estate (3559)
Recruiting (30)
Regulatory (15067)
Reports (27)
Research institute (1190)
Resumes & cover letters (149)
Rett syndrome (7)
RNA editing (6)
RSV (42)
Schizophrenia (86)
Series A (116)
Series B (69)
Service/supplier (9)
Sickle cell disease (54)
Special edition (19)
Spinal muscular atrophy (120)
Sponsored (15)
Startups (2219)
State (2)
Stomach cancer (15)
Supply chain (71)
Tariffs (69)
The Weekly (68)
Vaccines (428)
Venture capital (45)
Weight loss (276)
Women's health (28)
Worklife (8)
Date
Today (84)
Last 7 days (400)
Last 30 days (1332)
Last 365 days (23693)
2025 (13878)
2024 (24349)
2023 (26258)
2022 (33510)
2021 (34903)
2020 (32714)
2019 (26562)
2018 (20462)
2017 (21282)
2016 (20272)
2015 (23858)
2014 (18786)
2013 (15384)
2012 (16573)
2011 (17209)
2010 (15682)
Location
Africa (451)
Alabama (42)
Alaska (2)
Arizona (103)
Arkansas (10)
Asia (28646)
Australia (4101)
California (5504)
Canada (1783)
China (571)
Colorado (226)
Connecticut (257)
Delaware (181)
Europe (62210)
Florida (804)
Georgia (144)
Hawaii (2)
Idaho (23)
Illinois (489)
India (27)
Indiana (269)
Iowa (9)
Japan (223)
Kansas (74)
Kentucky (25)
Louisiana (6)
Maine (25)
Maryland (690)
Massachusetts (4350)
Michigan (124)
Minnesota (283)
Mississippi (3)
Missouri (80)
Montana (12)
Nebraska (12)
Nevada (50)
New Hampshire (24)
New Jersey (1691)
New Mexico (23)
New York (1503)
North Carolina (759)
North Dakota (4)
Northern California (2395)
Ohio (150)
Oklahoma (10)
Oregon (23)
Pennsylvania (1091)
Puerto Rico (16)
Rhode Island (22)
South America (676)
South Carolina (9)
Southern California (2139)
Tennessee (78)
Texas (800)
United States (20216)
Utah (141)
Virginia (175)
Washington D.C. (63)
Washington State (478)
West Virginia (2)
Wisconsin (66)
434,378 Results for "purdue pharma l p".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Purdue Pharma L.P. Awards Grant for Investigator-initiated Research to Examine Opioid Overdose Reversal Using Nalmefene HCl Injection
Purdue Pharma L.P. (“Purdue”) announced today that the Company has awarded an investigator-initiated research (IIR) grant to a team of researchers at The University of New Mexico (UNM) for the evaluation of nalmefene hydrochloride (HCl) injection 2mg/2mL (1mg/1mL) in the emergency department setting.
March 27, 2024
·
7 min read
Bankruptcy
Purdue Files for Bankruptcy Anew to Support $7.4B+ Opioid Settlement
The Supreme Court last year blocked a previous settlement proposal from Purdue, arguing that the plan would afford the Sackler family too much protection.
March 20, 2025
·
2 min read
·
Tristan Manalac
Legal
Purdue Pharma, Sacklers Settle Opioid Lawsuits For $7.4B
The settlement is the largest deal to date with the people primarily who played an “instrumental role” in driving the opioid crisis, according to the office of Massachusetts Attorney General Andrea Joy Campbell.
January 24, 2025
·
2 min read
·
Tristan Manalac
Job Trends
Amidst Industry Challenges, 85% of Pharmas Increase Investment in AI
A new report found that 85% of pharma respondents are increasing their artificial intelligence investments, and 70% see AI as an immediate priority. Two experts discuss how biopharmas are implementing and adopting AI, including their increased use of external help with the process.
July 31, 2025
·
4 min read
·
Angela Gabriel
Earnings
AstraZeneca CEO Says World ‘Needs to Share’ in Global Pharma R&D
Pascal Soriot’s comments came during AstraZeneca’s Q2 earnings call in regard to President Donald Trump’s newly announced European pharma tariffs. The company also announced estimate-beating earnings, with its cancer portfolio driving earnings despite clinical roadblocks.
July 29, 2025
·
3 min read
·
Tristan Manalac
Pharm Country
Purdue Pharma L.P. to Provide Funding Opportunities for Investigator-Initiated Research to Examine Opioid Overdose Reversal Using Nalmefene HCl Injection
Purdue Pharma L.P. is accepting proposals for investigator-initiated research (IIR) to examine the outcomes associated with the use of Nalmefene Hydrochloride injection, 2mg/2mL (1mg/1mL).
March 28, 2023
·
6 min read
Press Releases
Yamo Pharma Presents Statistically Significant Phase 2 Autism Results for L1-79 at INSAR 2025
Trial achieves unprecedented and clinically meaningful socialization gains in adolescents and young adults, addressing core autism symptoms currently lacking FDA-approved therapies.
May 8, 2025
·
1 min read
Press Releases
Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation
May 12, 2025
·
5 min read
Deals
Revolution Establishes Endless Cash Runway With $2B Royalty Pharma Deal
In May, Revolution Medicines projected its cash and equivalents of $2.1 billion would last into the second half of 2027. With new funding from Royalty Pharma, the biotech has withdrawn that runway end date.
June 24, 2025
·
1 min read
·
Annalee Armstrong
Deals
Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
Agile Therapeutics, Inc. today announced that it has entered into a definitive merger agreement (“Merger Agreement”) with Insud Pharma, S.L.
June 26, 2024
·
10 min read
1 of 43,438
Next
